CTOs on the Move

Nanoscope Therapeutics

www.nanostherapeutics.com

 
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

OmniSonics Medical Technologies

At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial

Albion Laboratories

Albion Laboratories is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lively

Lively provides hearing devices from the convenience of your home, all under the guidance of a doctor for 50% less than the national average.

Affinity Health & Wellness

Affinity Health & Wellness is a medical marijuana dispensary located in New Haven, CT that aims to create a relationship with each patient built on compassion, trust and optimal outcomes.

PharmaBlock Sciences

PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs; and FTE services. The company was listed on Shenzhen Exchange Stock in China on November 10, 2017. PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Building on that success, the company acquired Shandong Diai Biotechnology Co., Ltd. as its pilot plant and manufacturing site in 2016, and is providing scale-up synthesis and manufacturing of key intermediates/RSMs. PharmaBlock is now committed to a more comprehensive and long-term service to valued customers.